[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617890":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":34,"responsibleParty":52,"collaborators":18,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":18,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":18,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":76,"overallStatus":37,"whyStopped":18,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Pontificia Universidad Catolica de Chile","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intravenous dexamethasone","ACTIVE_COMPARATOR","cccc",[13],"Drug: administration of dexamethasone intravenously",{"label":15,"type":16,"description":17,"interventionNames":18},"Local dexamethasone","NO_INTERVENTION","ccc",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","administration of dexamethasone intravenously","IV dexamethasone administration will be added to the interscalene block. In the control group, dexamethasone will be applied perineurally.",[9],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Andrea Araneda, MD","CONTACT","56955043270","andreaaraneda10@gmail.com",{"name":32,"role":28,"phone":29,"phoneExt":18,"email":33},"Ricardo Fuentes, MD","rsfuente@uc.cl",[35],{"facility":36,"status":37,"city":38,"state":18,"zip":18,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Red Salud UCChristus","RECRUITING","Santiago","Chile","CL",{"type":42,"coordinates":43},"Point",[44,45],-70.64827,-33.45694,{"lat":45,"lon":44},[48],{"name":49,"role":28,"phone":50,"phoneExt":18,"email":51},"Victor Contreras, MSN","56981895232","vecontre@uc.cl",{"type":53,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100617890","effect-of-dexamethasone-on-plasma-levels-of-bupivacaine-and-dexamethasone-after-a-single-injection-interscalene-nerve-block-100617890",false,"NCT07324499","Effect of Dexamethasone on Plasma Levels of Bupivacaine and Dexamethasone After a Single-injection Interscalene Nerve Block.","Effect of Dexamethasone on Plasma Levels of Bupivacaine and Dexamethasone Following a Single-injection Interscalene Nerve Block: A Randomized Controlled Study","Inclusion Criteria:\n\n\\- ASA I-II patients, with a body mass index (BMI) between 20 and 34 kg\u002Fm2 scheduled for shoulder surgery requiring single-needle interscalene block\n\nExclusion Criteria:\n\n\\- Chronic opioid use, liver failure, kidney failure, allergy to protocol drugs","ALL","18 Years","90 Years",{"count":65,"type":66},40,"ESTIMATED","INTERVENTIONAL",[69],"NA","Recent studies have highlighted the comparative advantages of perineural dexamethasone, particularly regarding its safety profile and its ability to prolong analgesia in various peripheral nerve blocks. A recent systematic review demonstrated that perineural administration of dexamethasone significantly extends the duration of analgesia compared to intravenous administration.\n\nThe mechanism of action of perineural dexamethasone remains unclear. Moreover, there is a lack of research comparing the systemic absorption of local anesthetics administered perineurally with or without dexamethasone, and the systemic absorption and bioavailability of dexamethasone when used as a perineural adjuvant have not been studied.\n\nObjective: This study aims to compare plasma concentrations of bupivacaine following a single-shot interscalene block with dexamethasone administered either perineurally or intravenously.\n\nMethodology: A prospective, randomized, double-blind trial will be conducted involving 40 patients undergoing shoulder surgery requiring a single-shot interscalene block. Each patient will receive 20 mL of 0.25% bupivacaine combined with 8 mg of dexamethasone administered either perineurally or intravenously. Venous blood samples (5 mL) will be collected at 5, 10, 20, 40, 80, 120, and 240 minutes post-block, and one sample at discharge, to measure plasma concentrations of both enantiomers of bupivacaine (D(+)-bupivacaine and L(-)-bupivacaine) and dexamethasone.\n\nOutcomes: The study will compare plasma levels of bupivacaine between groups, characterize the pharmacokinetics of bupivacaine and dexamethasone, and assess block duration and opioid consumption.",[72,73,74,75],"Pain","Interscalene Blocks","Dexamethasone","Bupivacaine",[74,75,72,77],"Interscalene blocks","2026-08-09",{"date":80,"type":81},"2026-08-12","ACTUAL",{"date":83,"type":81},"2026-05-19",{"date":85,"type":66},"2027-12-01",{"name":5,"class":6},1]